Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm
Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Pharmaceuticals Progresses With Global Schizophrenia Trial
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia –– Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia ––
Reviva Pharmaceuticals Q1 EPS $(0.25) Beats $(0.42) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. This is a 16.67 percent increase over losses
Reviva Pharmaceuticals Operational Performance Insights
10-Q: Quarterly report
Reviva Pharm Holdings 1Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings 1Q Loss/Shr 25c >RVPH
Press Release: Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Appli
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia –– Registrational RECOVER-2 trial expected t
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
CUPERTINO, Calif., May 13, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm
Press Release: Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDA
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
CUPERTINO, Calif., May 09, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm
HC Wainwright & Co. : Reviva Pharmaceuticals (RVPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : Reviva Pharmaceuticals (RVPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals with a Buy and maintains $20 price target.
AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug
Benchmark: Revised Reviva Pharmaceuticals (RVPH.US) rating and adjusted from Speculative Buy to Specified Buy, target price $17.00.
Benchmark: Revised Reviva Pharmaceuticals (RVPH.US) rating and adjusted from Speculative Buy to Specified Buy, target price $17.00.
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 price target.
Reviva Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 398.53% Benchmark → $17 Reiterates Speculative Buy → Speculative Buy 03/25/2024 486.51% HC Wain
No Data